lipase A, lysosomal acid typeGenealiases: CESD · LAL
Q-omics provides the consensus-scored LIPA profile across patient tissues and cancer cell-line models. LIPA expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LIPA is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, LIPA protein abundance shows 20,330 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where LIPA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIPA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIPA survival associations across molecular data types. LIPA RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIPA RNA expression–survival associations across cancer types. High LIPA expression shows unfavorable associations in UVM, ACC, LAML and BLCA, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LIPA RNA expression.
This table summarizes LIPA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LIPA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIPA shows lower tumor expression in LUSC, LUAD and KICH and higher tumor expression in KIRC, HNSC and KIRP. The KIRC box plot shows higher LIPA RNA expression in tumor versus normal tissue (log2 FC = +1.452, t-test p < 0.001).
This table shows molecular features associated with LIPA in patient tissues and cancer cell lines. In patient samples, LIPA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LIPA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
